Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
CVM

CVM - CEL-SCI Corp Stock Price, Fair Value and News

1.26USD+0.02 (+1.61%)Market Closed

Market Summary

CVM
USD1.26+0.02
Market Closed
1.61%

CVM Stock Price

View Fullscreen

CVM RSI Chart

CVM Valuation

Market Cap

68.2M

Price/Earnings (Trailing)

-2.28

Price/Sales (Trailing)

167.36

EV/EBITDA

-2.41

Price/Free Cashflow

-3.35

CVM Price/Sales (Trailing)

CVM Profitability

EBT Margin

-7536.20%

Return on Equity

-209.39%

Return on Assets

-99.68%

Free Cashflow Yield

-29.86%

CVM Fundamentals

CVM Revenue

Revenue (TTM)

462.8K

CVM Earnings

Earnings (TTM)

-30.0M

Earnings Growth (Yr)

13.16%

Earnings Growth (Qtr)

-7.98%

Breaking Down CVM Revenue

Last 7 days

4.1%

Last 30 days

-5.3%

Last 90 days

-22.7%

Trailing 12 Months

-46.2%

How does CVM drawdown profile look like?

CVM Financial Health

Current Ratio

1.67

CVM Investor Care

Shares Dilution (1Y)

21.12%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2019469.7K466.2K462.8K0
201800476.6K473.1K
2017207.5K342.0K00
201698.0K85.5K73.0K0
2015116.9K112.5K110.5K0
2014120.0K121.4K122.9K120.2K
2013116.6K116.8K117.1K118.5K
2012536.1K326.1K116.1K116.3K
2011554.7K755.4K956.2K746.1K
20100116.7K153.3K354.0K
20090080.1K0

Tracking the Latest Insider Buys and Sells of CEL-SCI Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 28, 2024
talor eyal
acquired
2,398
1.16
2,068
chief scientific officer
Jun 28, 2024
prichep patricia b
acquired
4,289
1.16
3,698
senior vice president
Jun 28, 2024
kersten geert r
acquired
5,174
1.16
4,461
chief executive officer
May 08, 2024
watson robert eugene
bought
27,800
1.39
20,000
-
May 08, 2024
prichep patricia b
bought
11,120
1.39
8,000
senior vice president
May 08, 2024
kersten geert r
bought
41,700
1.39
30,000
chief executive officer
Mar 29, 2024
talor eyal
acquired
2,398
1.91
1,256
chief scientific officer
Mar 29, 2024
prichep patricia b
acquired
4,289
1.91
2,246
senior vice president
Mar 29, 2024
kersten geert r
acquired
5,174
1.91
2,709
chief executive officer
Dec 29, 2023
talor eyal
acquired
2,399
2.72
882
chief scientific officer

1–10 of 50

Which funds bought or sold CVM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 12, 2024
Hyperion Partners, LLC
added
7.09
-9,415
17,516
0.01%
Jul 10, 2024
NBC SECURITIES, INC.
sold off
-100
-1,000
-
-%
Jul 09, 2024
City State Bank
unchanged
-
-1,680
2,320
-%
May 20, 2024
Virtu Financial LLC
reduced
-70.41
-129,000
34,000
-%
May 16, 2024
Tidal Investments LLC
new
-
26,532
26,532
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-2.24
-51,360
112,458
-%
May 15, 2024
Community Bank, N.A.
unchanged
-
-410
950
-%
May 15, 2024
STATE STREET CORP
unchanged
-
-157,146
370,553
-%
May 15, 2024
MORGAN STANLEY
reduced
-58.25
-83,435
34,608
-%
May 15, 2024
AMERIPRISE FINANCIAL INC
unchanged
-
-12,571
29,643
-%

1–10 of 46

Are Funds Buying or Selling CVM?

Are funds buying CVM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CVM
No. of Funds

Unveiling CEL-SCI Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 08, 2023
state street corp
0.5%
218,207
SC 13G/A
Jul 08, 2022
blackrock inc.
2.7%
1,153,102
SC 13G
Apr 11, 2022
state street corp
2.27%
980,339
SC 13G/A
Feb 11, 2022
state street corp
7.79%
3,368,998
SC 13G/A
Feb 01, 2022
blackrock inc.
6.8%
2,942,209
SC 13G/A
Oct 12, 2021
state street corp
10.64%
4,576,724
SC 13G/A
Jan 29, 2021
blackrock inc.
6.2%
2,472,437
SC 13G/A
Feb 07, 2020
blackrock inc.
5.6%
1,996,547
SC 13G

Recent SEC filings of CEL-SCI Corp

View All Filings
Date Filed Form Type Document
Jul 01, 2024
4
Insider Trading
Jul 01, 2024
4
Insider Trading
Jul 01, 2024
4
Insider Trading
Jun 20, 2024
8-K
Current Report
May 15, 2024
10-Q
Quarterly Report
May 10, 2024
4
Insider Trading
May 09, 2024
4
Insider Trading
May 09, 2024
4
Insider Trading
Apr 23, 2024
8-K
Current Report
Apr 23, 2024
4
Insider Trading

Peers (Alternatives to CEL-SCI Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.5B
6.8B
-17.79% -4.08%
-7.8
6.8
-64.45% -224.75%
33.0B
2.0B
63.81% 27.79%
-99.24
16.45
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
0.60% -0.76%
78.61
6.53
13.74% 186.89%
14.3B
3.8B
6.19% 2.76%
19.17
3.79
8.58% 129.81%
MID-CAP
5.1B
107.9M
-5.51% 56.56%
-9.28
48.09
54.84% -28.31%
4.8B
524.1M
-6.99% -54.02%
-11.5
9.15
394.93% 39.61%
3.9B
251.0M
15.74% 13.44%
-13.27
15.67
73.58% -86.73%
3.5B
240.7M
9.12% -18.47%
-7.38
12.77
-1.03% -213.92%
2.9B
813.8M
15.55% -31.16%
-1.7K
3.61
56.43% 98.83%
1.8B
996.6M
-17.40% 41.77%
-4.61
1.85
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
7.18% 31.22%
30.04
4.76
60.38% -34.49%
628.3M
881.7K
14.71% 639.50%
-18.61
481.06
-77.61% 33.36%
293.1M
4.2M
19.30% 68.30%
-2.35
70.45
-66.30% 48.24%
21.0M
2.1M
-4.31% -79.32%
-0.91
7.61
-13.45% 69.54%

CEL-SCI Corp News

Latest updates
MarketBeat8 hours ago
American Banking and Market News11 Jul 202406:42 am
StockTitan08 Jul 202401:15 pm

CEL-SCI Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2019Q32019Q22019Q12018Q42018Q32017Q22017Q12016Q32016Q22016Q12015Q32015Q22015Q12014Q42014Q32014Q22014Q12013Q42013Q32013Q22013Q1
Revenue-----0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Operating Expenses7.5%6.005.004.005.004.00----------------
  S&GA Expenses-1.0%2.002.002.002.001.00----------------
  R&D Expenses14.3%3.003.003.003.003.00----------------
Interest Expenses-0.7%-0.45-0.44-0.46-0.455.00----------------
Earnings Before Taxes-Infinity%-4.85--------------------
Net Income59.9%-4.85-12.08-6.451.00-14.93----------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets4.7%30.0029.0031.0032.0038.0045.0051.0057.0064.0070.0076.0080.0048.0050.0041.0044.0037.0031.0028.0028.0025.00
  Current Assets38.3%9.006.007.008.0013.0020.0025.0031.0037.0042.0045.0050.0020.0024.0018.0023.0016.0011.0010.0011.007.00
    Cash Equivalents63.8%5.003.004.005.0010.0018.0023.0028.0034.0037.0036.0036.006.0022.0016.0020.0014.009.008.009.006.00
  Inventory-100.0%-2.002.00---2.00---2.002.001.001.001.001.001.001.001.001.001.00
  Net PPE-5.5%9.0010.0010.0011.0011.0012.0012.0012.0013.0013.0014.0014.0013.009.006.004.003.003.0016.0016.0016.00
Liabilities-2.0%16.0016.0017.0018.0018.0018.0018.0018.0019.0018.0019.0020.0019.0021.0021.0023.0023.0023.0022.0027.0024.00
  Current Liabilities4.5%5.005.006.005.005.005.005.004.004.003.004.005.006.007.004.005.005.005.003.004.005.00
Shareholder's Equity13.1%14.0013.0013.0015.0020.0027.0032.0039.0045.0051.0057.0060.0029.0029.0020.0021.0014.009.005.001.001.00
  Retained Earnings-1.5%-501-493-487-479-471-462-454-446-436-426-418-409-401-389-381-376-366-357-353-348-336
  Additional Paid-In Capital1.8%515506500494491489487485481478474469430418401397380366359350337
Shares Outstanding8.1%54.0050.0047.0045.0044.0044.0043.0043.0043.0043.0043.0040.00---------
Float---------98.00---596---412---100
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations7.4%-4,527-4,887-5,044-5,665-7,471-4,666-4,913-5,789-2,731-4,805-4,802-5,200-4,956-3,827-3,586-3,699-3,888-4,101-3,887-4,643-3,632
  Share Based Compensation3.5%1,4331,3841,3101,5401,7431,6932,2872,4483,3933,2623,5953,5113,2833,2963,4233,1091,7811,8001,8021,522531
Cashflow From Investing100.0%--64.86-10.37-196-111-53.58-16.07-70.96-5336,1124,590-1,999-14,624-3,149-1,124-803-657-109-49.04-58.22-156
Cashflow From Financing62.9%6,5964,0484,066952-38865.00-471-348438-25631536,7264,15213,32983.0010,3109,4925,1502,8958,6732,621
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CVM Income Statement

2024-03-31
CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)    
Research and development$ 4,628,535$ 6,083,488$ 8,981,044$ 11,476,034
General and administrative2,447,4132,092,7584,580,7914,350,761
Total operating expenses7,075,9488,176,24613,561,83515,826,795
Operating loss(7,075,948)(8,176,246)(13,561,835)(15,826,795)
Interest expense, net(182,701)(159,063)(380,397)(311,852)
Other expense(13,758)(7,500)(12,183)(57,671)
Net loss(7,244,891)(8,342,809)(13,954,415)(16,196,318)
Modification of warrants  0(171,552)
Net loss available to common shareholders$ (7,244,891)$ (8,342,809)$ (13,954,415)$ (16,367,870)
Net loss per common share - basic and diluted$ (0.14)$ (0.19)$ (0.28)$ (0.38)
Weighted average common shares outstanding - basic and diluted52,006,44243,588,38150,228,86043,513,571

CVM Balance Sheet

2024-03-31
CONDENSED BALANCE SHEETS - USD ($)
Mar. 31, 2024
Sep. 30, 2023
Current assets:  
Cash and cash equivalents$ 5,309,321$ 4,145,735
Prepaid expenses696,648520,368
Supplies used for R&D and manufacturing2,489,2842,248,072
Deposits16,1294,245
Total current assets8,511,3826,918,420
Finance lease right of use assets8,251,4539,131,987
Operating lease right of use assets1,598,8791,698,243
Property and equipment, net9,113,28410,188,126
Patent costs, net180,482197,704
Deposits2,319,1012,319,101
Supplies used for R&D and manufacturing73,52474,669
Total assets30,048,10530,528,250
Current liabilities:  
Accounts payable1,015,9692,009,786
Accrued expenses1,219,3991,049,581
Due to employees751,607557,244
Finance lease obligation, current portion1,888,7671,771,804
Operating lease obligation, current portion211,275197,431
Total current liabilities5,087,0175,585,846
Finance lease obligations, net of current portion8,987,3199,949,565
Operating lease obligations, net of current portion1,544,1261,652,949
Other liabilities125,000125,000
Total liabilities15,743,46217,313,360
STOCKHOLDERS' EQUITY  
Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding00
Common stock, $.01 par value; 600,000,000 shares authorized; 54,083,718 and 47,422,304 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively540,837474,223
Additional paid-in capital514,809,617499,832,063
Accumulated deficit(501,045,811)(487,091,396)
Total stockholders' equity14,304,64313,214,890
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 30,048,105$ 30,528,250
CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
0
 WEBSITEhttps://cel-sci.com
 INDUSTRYBiotechnology

CEL-SCI Corp Frequently Asked Questions


What is the ticker symbol for CEL-SCI Corp? What does CVM stand for in stocks?

CVM is the stock ticker symbol of CEL-SCI Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CEL-SCI Corp (CVM)?

As of Fri Jul 12 2024, market cap of CEL-SCI Corp is 68.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CVM stock?

You can check CVM's fair value in chart for subscribers.

What is the fair value of CVM stock?

You can check CVM's fair value in chart for subscribers. The fair value of CEL-SCI Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CEL-SCI Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CVM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CEL-SCI Corp a good stock to buy?

The fair value guage provides a quick view whether CVM is over valued or under valued. Whether CEL-SCI Corp is cheap or expensive depends on the assumptions which impact CEL-SCI Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CVM.

What is CEL-SCI Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 12 2024, CVM's PE ratio (Price to Earnings) is -2.28 and Price to Sales (PS) ratio is 167.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CVM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CEL-SCI Corp's stock?

In the past 10 years, CEL-SCI Corp has provided -0.275 (multiply by 100 for percentage) rate of return.